Consistently Low Serum Levels of MG-H1 Are Associated With a Lower Risk of Diabetic Kidney Disease
The Journal of Clinical Endocrinology & Metabolism · 2025
DOI: 10.1210/clinem/dgaf098 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Tomoka Nakamura und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diabetes, Endocrinology, and Metabolism, Center Hospital, National Center for Global Health and Medicine, Tokyo 162-8655, Japan. Hauptthemen laut MEDLINE: Diabetic Nephropathies, Glycation End Products, Advanced, Imidazoles, Pyruvaldehyde. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: National Center for Global Health and Medicine Intramural Research Fund.
Abstract (Originalsprache)
Context
Diabetic kidney disease (DKD) is associated with an increased risk of cardiovascular events, end-stage renal disease, and mortality. Advanced glycation end products (AGEs) are related to DKD. However, data on the associations between long-term changes in AGEs and DKD are lacking.
Objective
We aimed to ascertain whether a long-term shift in serum AGE levels is associated with DKD development and progression in patients with poorly controlled diabetes.
Methods
The serum levels of the AGE, methylglyoxal-derived hydroimidazolone-1 (MG-H1) were measured twice in 160 patients with diabetes. We categorized patients whose serum MG-H1 levels were <2.5 µg/mL at both measurements as the consistently low MG-H1 group. The primary endpoints were new or worsening DKD, which was defined as the occurrence of either a 30% decline in estimated glomerular filtration rate (eGFR), doubling of serum creatinine, development of macroalbuminuria, need for renal replacement therapy, or death due to renal disease. Hazard ratios (HRs) for new or worsening DKD, with 95% confidence intervals (CIs), were calculated using Cox proportional hazard models to compare the outcomes between the consistently low MG-H1 group and the other group.
Results
Compared to the other group, the consistently low MG-H1 group had a significantly lower risk of new or worsening DKD, after adjusting for possible confounders (HR: 0.48; 95% CI, 0.29–0.81; P = .01). Furthermore, the same relationship was observed in patients without eGFR <30 mL/min/1.73 m2, advanced DKD, or cardiovascular events.
Conclusion
Consistently low serum MG-H1 levels are associated with a lower frequency of DKD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Diabetes, Endocrinology, and Metabolism, Center Hospital, National Center for Global Health and Medicine, Tokyo 162-8655, Japan.
- Department of Diabetes and Endocrinology, Toranomon Hospital Kajigaya, Kanagawa 213-0015, Japan.
- Department of Diabetes, Endocrinology and Metabolism, Kyorin University School of Medicine, Tokyo 181-8611, Japan.
- Department of Molecular Diabetic Medicine, Diabetes Research Center, Research Institute, National Center for Global Health and Medicine, Tokyo 162-8655, Japan.
ORCID-Profile: Tetsuro Tsujimoto
Förderung
- National Center for Global Health and Medicine Intramural Research Fund
Zitieren
APA
Nakamura, T., Tsujimoto, T., Yasuda, K., Kajio, H., & Ueki, K. (2025). Consistently Low Serum Levels of MG-H1 Are Associated With a Lower Risk of Diabetic Kidney Disease. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaf098
Vancouver
Nakamura T, Tsujimoto T, Yasuda K, Kajio H, Ueki K. Consistently Low Serum Levels of MG-H1 Are Associated With a Lower Risk of Diabetic Kidney Disease. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgaf098
BibTeX
@article{Nakamura2025,
author = {Nakamura, Tomoka and Tsujimoto, Tetsuro and Yasuda, Kazuki and Kajio, Hiroshi and Ueki, Kohjiro},
title = {Consistently Low Serum Levels of MG-H1 Are Associated With a Lower Risk of Diabetic Kidney Disease},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
doi = {10.1210/clinem/dgaf098}
}
EUVIMED